Active

Psoriatic Arthritis

Active

Ankylosing Spondylitis

Moderate to Severe

Juvenile Idiopathic Arthritis

Non-Infectious

Intermediate, Posterior and Panuveitis

Active

Psoriatic Arthritis

Moderate to Severe

Hidradenitis Suppurativa

Gastroenterology

Moderate to Severe

Crohn's Disease

Moderate to Severe

Pediatric Crohn's Disease

Moderate to Severe

Ulcerative Colitis

Moderate to Severe

Pediatric Ulcerative Colitis

Ophthalmology

Non-Infectious

Intermediate, Posterior and Panuveitis

WEEK 16

Picture what improvement could look like

SEE ACTUAL PSORIASIS PATIENTS TREATED
WITH SKYRIZI (risankizumab-rzaa)2

Photo depicts moderate to severe plaque psoriasis patient with affected body surface area ≥10% at baseline, outside of clinical trials.

PRIMARY DATA FROM PIVOTAL TRIALS

Week 16

Patient results after 2 doses at Week 16


Patient photos representing results captured at baseline and Week 16, outside of clinical trials. PASI and sPGA achievement undefined.2

The patients depicted here have moderate to severe plaque psoriasis with an affected body surface area ≥10%.

Photos courtesy of Dr. Meyer Horn.2

Patient results after 2 doses of SKYRIZI® at Week 16
Patient condition before starting SKYRIZI® at Week 0

BEFORE | WEEK 0

AFTER | WEEK 16

Patient from Illinois

Week 16

Patient results after 2 doses at Week 16


Patient photos representing results captured at baseline and Week 16, outside of clinical trials. PASI and sPGA achievement undefined.2

The patients depicted here have moderate to severe plaque psoriasis with an affected body surface area ≥10%.

Photos courtesy of Matthew Insley, RPA-C.2

Patient results after 2 doses of SKYRIZI® at Week 16
Patient condition before starting SKYRIZI® at Week 0

BEFORE | WEEK 0

AFTER | WEEK 16

Patient from New York

Week 16

Patient results after 2 doses at Week 16


Patient photos representing results captured at baseline and Week 16, outside of clinical trials. PASI and sPGA achievement undefined.2

The patients depicted here have moderate to severe plaque psoriasis with an affected body surface area ≥10%.

Photos courtesy of Victor Czerkasij, FNP-C.2

Patient results after 2 doses of SKYRIZI® at week 16
Patient condition before starting SKYRIZI® at Week 0

BEFORE | WEEK 0

AFTER | WEEK 16

Patient from Tennessee

Week 16

Patient results after 2 doses at Week 16


Patient photos representing results captured at baseline and Week 16, outside of clinical trials. PASI and sPGA achievement undefined.2

The patients depicted here have moderate to severe plaque psoriasis with an affected body surface area ≥10%.

Photos courtesy of Dr. Ellen Frankel.2

Patient results after 2 doses of SKYRIZI® at Week 16
Patient condition before starting SKYRIZI® at Week 0

BEFORE | WEEK 0

AFTER | WEEK 16

Patient from Rhode Island

Patient results after 5 doses SKYRIZI® at Week 52
Patient condition before starting SKYRIZI® at Week 0

BEFORE | WEEK 0

AFTER | WEEK 52

Patient from Illinois

Week 52

Patient results after 5 doses at Week 52


Patient photos representing results captured at baseline and Week 52, outside of clinical trials. PASI and sPGA achievement undefined.2

The patients depicted here have moderate to severe plaque psoriasis with an affected body surface area ≥10%.

Photos courtesy of Dr. Meyer Horn.2


Well-Studied Safety Profile

across 4 pivotal trials1

Checklist Icon

Only 4 doses per year

3-month dosing after 2 initiation doses at
Weeks 0 and 4 (150 mg/dose)1

Calendar icon
ISI and Indication
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Indication

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information

Infection

SKYRIZI® (risankizumab-rzaa) may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

Please see Full Prescribing Information.

US-SKZD-210127

REFERENCES

  1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
  2. Data on file, ABVRRTI70545.
  3. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650-661.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Indication

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information

Infection

SKYRIZI® (risankizumab-rzaa) may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

Please see Full Prescribing Information.

US-SKZD-210127